Russell Investments Group Ltd. Has $33.15 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Russell Investments Group Ltd. lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 17.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,579 shares of the company’s stock after selling 13,930 shares during the quarter. Russell Investments Group Ltd.’s holdings in Medpace were worth $33,153,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Quent Capital LLC acquired a new position in Medpace during the third quarter valued at approximately $25,000. Optiver Holding B.V. acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $27,000. Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Employees Retirement System of Texas bought a new position in shares of Medpace in the second quarter valued at $36,000. Finally, Root Financial Partners LLC acquired a new position in Medpace during the third quarter worth $38,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Barclays raised shares of Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 target price on the stock in a report on Friday, March 6th. Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. Finally, Royal Bank Of Canada initiated coverage on shares of Medpace in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $486.67.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $477.72 on Thursday. The business has a fifty day moving average price of $528.39 and a two-hundred day moving average price of $539.24. The stock has a market capitalization of $13.56 billion, a PE ratio of 31.22, a P/E/G ratio of 2.24 and a beta of 1.44. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.